U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
NDA FilingEcopipamPositive
AI Analysis
Summary
Teva announced FDA acceptance of its NDA for Ecopipam, a first-in-class investigational therapy for pediatric Tourette Syndrome, with Priority Review granted. The Priority Review status accelerates the FDA review timeline.
Outcome Details
FDA accepted NDA and granted Priority Review
Importance:8/10
Sentiment:
0.80
FDANDAPriority ReviewFirst-in-ClassPediatricTourette Syndrome
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on August 19, 2026 9:08 PM